about
Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, CanadaSequencing of the Hepatitis C Virus: A Systematic Review.The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at -20°C and -70°C.Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing.A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events.Presence of hepatitis C virus in syringes confiscated in prisons in Australia.Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolic-androgenic steroid users.Infectious disease screening of blood specimens collected post-mortem provides comparable results to pre-mortem specimens.Trends in PIEDs use among male clients of needle–syringe programs in Queensland, Australia; 2007–2015Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugsA latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugsTransitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?Health care engagement behaviors of men who use performance- and image-enhancing drugs in AustraliaPrevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in CanadaTrends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007-2015Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, CanadaEvaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort studyReal-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs
P50
Q34415820-65CFE14E-3C90-4559-B192-88B4349FA13BQ34796385-BFEDBBB2-95EE-4F31-9606-A3378B0ADD06Q35698428-4A3B1D40-C67C-42B1-A652-8274954EEA22Q35703205-243F6A6F-9F21-4A0D-81D6-F3427554FCA1Q36120059-0B353F6A-44C8-497E-A19E-37F1687FD939Q36134478-CEBA16F5-12BD-4768-A0CF-56B0CF8F597EQ36506119-D368986E-F070-478E-8698-C6D28E9297C1Q36922133-B710D5BE-AE27-44F2-9B88-01449F7AFB88Q38285134-890CF7A5-3442-4D96-98EE-5AF6B5D388CDQ40118634-6D46A8DC-A6EC-4CF5-91A8-1D7A34DDD94FQ40709549-DC2845D3-140B-46DB-BB77-5AD5F4EB0FCEQ41281705-B0E57DBA-43D0-48A0-854A-34C59EBA4877Q42991378-063617CE-581D-4222-97A4-DD08D353FBE8Q52683800-2C29D188-F621-486E-AE9E-1D975323D988Q53255332-6BE441D6-3ADE-4986-AB40-E09B52CF6961Q58235144-89DB17BB-4B08-4616-8237-FD9CB6D6FD17Q64080932-D94AC575-4247-4F0D-99FC-AF674255048AQ64236572-97C63C8B-AD78-4DE4-8200-6BCD72FD74D8Q90023097-44673800-42FE-4C33-B456-24EFE3C87DC9Q90211873-59CDD24C-C953-49B6-B311-FF4952EE9301Q90214320-153ABC25-1F0A-4B8D-ABCA-33910DB301A5Q91278684-3946795F-1B9F-4D1F-80A4-E0B491E4B990Q91564822-83A359BF-1BD5-4B92-8BD4-DED946642FD5Q92750535-E25F1261-6DCE-46FA-A6F4-FB4ABE10305CQ92861508-DA50E73A-5170-4280-AC2C-8E86DAD97471Q93042041-669376C6-774C-41EA-BBC9-70FB5E075BA0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brendan Jacka
@ast
Brendan Jacka
@en
Brendan Jacka
@es
Brendan Jacka
@nl
Brendan Jacka
@sl
type
label
Brendan Jacka
@ast
Brendan Jacka
@en
Brendan Jacka
@es
Brendan Jacka
@nl
Brendan Jacka
@sl
prefLabel
Brendan Jacka
@ast
Brendan Jacka
@en
Brendan Jacka
@es
Brendan Jacka
@nl
Brendan Jacka
@sl
P1053
T-3553-2018
P106
P1153
35310595000
P21
P31
P3829
P3835
brendan-jacka
P496
0000-0002-5910-853X